文献类型：期刊文献

中文题名：艾拉莫德联合雷公藤多苷片治疗类风湿关节炎效果及对膝关节功能的影响

英文题名：Effect of iguratimod combined with Tripterygium wilfordii multiglucoside tablets on rheumatoid arthritis and its impact on knee joint function

作者：李朝阳[1];韦全剑[1];刘海龙[2]

第一作者：李朝阳

机构：[1]临泉县人民医院风湿免疫科,安徽阜阳236400;[2]甘肃中医药大学附属医院风湿骨病科,甘肃兰州730030

第一机构：临泉县人民医院风湿免疫科,安徽阜阳236400

年份：2025

卷号：46

期号：11

起止页码：1145

中文期刊名：世界临床药物

外文期刊名：World Clinical Drug

语种：中文

中文关键词：艾拉莫德;雷公藤;类风湿关节炎;C反应蛋白;抗瓜氨酸肽抗体;膝关节功能

外文关键词：iguratimod;Tripterygium wilfordii;rheumatoid arthritis;C reactive protein;anticyclic citrullinated peptide antibody;knee joint function

摘要：目的探讨艾拉莫德联合雷公藤多苷片治疗类风湿关节炎(rheumatoid arthritis,RA)效果及对膝关节功能的影响。方法选择性纳入2022年1月至2024年12月临泉县人民医院接诊的RA患者130例进行研究,随机分为观察组和对照组,每组65例。对照组予艾拉莫德治疗,观察组予艾拉莫德联合雷公藤多苷片治疗。比较两组临床疗效、C反应蛋白(C reactive protein,CRP)、抗瓜氨酸肽抗体(anticyclic citrullinated peptide antibody,ACPA)、膝关节功能评分、积液深度、滑膜厚度及不良反应发生情况。结果治疗后,观察组治疗总有效率高于对照组(89.23%vs.73.85%,P<0.05)。两组血清CRP、ACPA水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。两组美国特种外科医院评分较治疗前均降低(P<0.05),且观察组低于对照组(P<0.05);两组Lysholm评分较治疗前均升高(P<0.05),且观察组高于对照组(P<0.05)。两组积液深度、滑膜厚度水平较治疗前降低(P<0.05),且观察组下降幅度更大(P<0.05)。观察组不良反应发生率低于对照组,但差异无统计学意义(12.31%vs.9.23%,P>0.05)。结论RA患者采用艾拉莫德联合雷公藤多苷片治疗可显著获益,其中雷公藤多苷片作为辅助治疗能有效降低CRP水平,抑制ACPA活性,并改善膝关节功能,且未增加不良反应风险,安全性良好。
Objective To explore the therapeutic effect of iguratimod combined with Tripterygium wilfordii multiglucoside tablets in the treatment of rheumatoid arthritis(RA)and its influence on knee joint function.Methods A total of 130 RA patients admitted to Linquan County People's Hospital from January 2022 to December 2024 were selectively included in the study and randomly divided into the observation group and the control group,with 65 cases in each group.The control group was treated with iguratimod,while the observation group was treated with iguratimod combined with Tripterygium wilfordii multiglucoside tablets.The clinical efficacy,C reactive protein(CRP),and anticyclic citrullinated peptide antibody(ACPA),knee joint function score,effusion depth,synovial thickness and the occurrence of adverse reactions of the two groups were compared.Results After treatment,the total effective rate of the observation group was higher than that of the control group(89.23%vs.73.85%,P<0.05).The levels of serum CRP and ACPA in both groups were lower than those before treatment(P<0.05),and those in the observation group were lower than those in the control group(P<0.05).The hospital for special surgery scores of both groups were lower than those before treatment(P<0.05),and the scores of the observation group were lower than those of the control group(P<0.05).The Lysholm scores of both groups were increased compared with those before treatment(P<0.05),and the scores of the observation group were higher than those of the control group(P<0.05).The depth of effusion and the thickness of synovial membrane in both groups were lower than those before treatment(P<0.05),and the decrease in the observation group was greater(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,but the difference was not statistically significant(12.31%vs.9.23%,P>0.05).Conclusion RA patients can benefit significantly from the treatment of iguratimod combined with Tripterygium wilfordii multiglucoside tablets.Among them,Tripterygium wilfordii multiglucoside tablets,as an adjuvant therapy,can effectively reduce CRP levels,inhibit ACPA activity,and improve knee joint function,without increasing the risk of adverse reactions,and has good safety.